

Mediclinic International plc  
(Incorporated in England and Wales)  
Company Number: 08338604  
LSE Share Code: MDC  
JSE Share Code: MEI  
NSX Share Code: MEP  
ISIN: GB00B8HX8Z88  
LEI: 2138002S5BSBIZTD5I60  
South African income tax number: 9432434182  
('Mediclinic', the 'Company', or the 'Group')

25 May 2023

**FORM 8 (DD)**

**PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)  
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the 'Code')**

**1. KEY INFORMATION**

<b>(a) Full name of discloser:</b>	Petrus Jurgens Myburgh
<b>(b) Owner or controller of interests and short positions disclosed, if different from 1(a):</b> <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
<b>(c) Name of offeror/offeree in relation to whose relevant securities this form relates:</b> <i>Use a separate form for each offeror/offeree</i>	Mediclinic International plc
<b>(d) Status of person making the disclosure:</b> <i>e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)</i>	Person acting in concert with the offeree (Mediclinic International plc)
<b>(e) Date dealing undertaken:</b>	24 May 2023
<b>(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?</b> <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

**2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE**

*If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.*

**(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing**

Class of relevant security:	Interests		Short positions	
	Number	% <sup>(1)</sup>	Number	%
<b>(1) Relevant securities owned and/or controlled:</b>	94 500 <sup>(2)</sup>	0.0128%	Nil	Nil
<b>(2) Cash-settled derivatives:</b>	Nil	Nil	Nil	Nil
<b>(3) Stock-settled derivatives</b>	Nil	Nil	Nil	Nil

<b>(including options) and agreements to purchase/sell:</b>				
<b>TOTAL:</b>	94 500	0.0128%	Nil	Nil

(1) Total number of ordinary shares of Mediclinic International plc is 737 243 810 as of 24 May 2023. The percentages have been rounded to the four nearest decimal places.

(2) Petrus Jurgens Myburgh owns 94 500 ordinary shares.

*All interests and all short positions should be disclosed.*

*Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).*

*Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).*

**(b) Rights to subscribe for new securities (including directors' and other employee options)**

<b>Class of relevant security in relation to which subscription right exists:</b>	N/A
<b>Details, including nature of the rights concerned and relevant percentages:</b>	N/A

**3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE**

*Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.*

*The currency of all prices and other monetary amounts should be stated.*

**(a) Purchases and sales**

**(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)**

<b>Class of relevant security</b>	<b>Purchase/sale</b>	<b>Number of securities</b>	<b>Price per unit</b>
N/A	N/A	N/A	N/A

**(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser**

<b>Class of relevant security</b>	<b>Purchases/sales</b>	<b>Total number of securities</b>	<b>Highest price per unit paid/received</b>	<b>Lowest price per unit paid/received</b>
N/A	N/A	N/A	N/A	N/A

**(b) Cash-settled derivative transactions**

<b>Class of relevant</b>	<b>Product description</b>	<b>Nature of dealing e.g. opening/closing a</b>	<b>Number of reference</b>	<b>Price per unit</b>
--------------------------	----------------------------	---	----------------------------	-----------------------

<b>security</b>	<i>e.g. CFD</i>	<i>long/short position, increasing/reducing a long/short position</i>	<b>securities</b>	
N/A	N/A	N/A	N/A	N/A

**(c) Stock-settled derivative transactions (including options)**

**(i) Writing, selling, purchasing or varying**

<b>Class of relevant security</b>	<b>Product description</b> <i>e.g. call option</i>	<b>Writing, purchasing, selling, varying etc.</b>	<b>Number of securities to which option relates</b>	<b>Exercise price per unit</b>	<b>Type</b> <i>e.g. American, European etc.</i>	<b>Expiry date</b>	<b>Option money paid/received per unit</b>
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

**(ii) Exercise**

<b>Class of relevant security</b>	<b>Product description</b> <i>e.g. call option</i>	<b>Exercising/ exercised against</b>	<b>Number of securities</b>	<b>Exercise price per unit</b>
N/A	N/A	N/A	N/A	N/A

**(d) Other dealings (including subscribing for new securities)**

<b>Class of relevant security</b>	<b>Nature of dealing</b> <i>e.g. subscription, conversion</i>	<b>Details</b>	<b>Price per unit (if applicable)</b>
Mediclinic International plc ordinary shares of 10 pence each	Vesting of awards granted under the Company's Short Term Incentive Plan	Vesting and cash settlement of awards over 128 143 ordinary shares in the Company under the Company's Short Term Incentive Plan following the sanctioning of the scheme of arrangement in relation to the recommended cash offer for the Company. Those awards will be settled in cash for 501 pence per share in accordance with the rules of the Short Term Incentive Plan.	N/A
Mediclinic International plc ordinary shares of 10 pence each	Vesting of awards granted under the Company's Long Term Incentive Plan	Vesting and cash settlement of awards over 216 953 ordinary shares in the Company under the Company's Long	N/A

		Term Incentive Plan following the sanctioning of the scheme of arrangement in relation to the recommended cash offer for the Company. Those awards will be settled in cash for 501 pence per share in accordance with the rules of the Long Term Incentive Plan.	
--	--	--	--

**4. OTHER INFORMATION**

**(a) Indemnity and other dealing arrangements**

<p><b>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:</b>  <i>Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"</i></p>
None.

**(b) Agreements, arrangements or understandings relating to options or derivatives**

<p><b>Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:</b>  <b>(i) the voting rights of any relevant securities under any option; or</b>  <b>(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:</b>  <i>If there are no such agreements, arrangements or understandings, state "none"</i></p>
None.

**(c) Attachments**

**Are any Supplemental Forms attached?**

<b>Supplemental Form 8 (Open Positions)</b>	NO
<b>Supplemental Form 8 (SBL)</b>	NO

<b>Date of disclosure:</b>	25 May 2023
<b>Contact name:</b>	Company Secretary, Link Company Matters Limited Caroline Emmet
<b>Telephone number:</b>	+44 (0)333 300 1930

*Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.*

*The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.*

*The Code can be viewed on the Panel's website at [www.thetakeoverpanel.org.uk](http://www.thetakeoverpanel.org.uk).*

## **CONTACT INFORMATION**

### **Investor queries**

James Arnold, Head of Investor Relations, Mediclinic International plc  
+44 (0)20 3786 8181  
[ir@mediclinic.com](mailto:ir@mediclinic.com)

### **Media queries**

FTI Consulting  
Ben Atwell/Ciara Martin – UK  
+44 (0)20 3727 1000  
Sherryn Schooling – South Africa  
+27 (0)21 487 9000

**Registered address:** 6<sup>th</sup> Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

**Website:** [www.mediclinic.com](http://www.mediclinic.com)

**Joint corporate brokers:** Morgan Stanley & Co International plc and UBS Investment Bank

**JSE sponsor (South Africa):** Rand Merchant Bank (A division of FirstRand Bank Ltd)

**NSX sponsor (Namibia):** Simonis Storm Securities (Pty) Ltd